丹心Ⅲ号和丹心Ⅴ号对血小板聚集功能的影响

本文观察了丹心Ⅲ号和丹心Ⅴ号对血小板聚集功能的影响,实验结果：丹心Ⅲ号和丹心Ⅴ号在体外均可显著抑制ＡＤＰ和花生四烯酸诱导的人血小板聚集,其ＩＣ５０分别为１．６０５ｍｇ／ｍｌ,２．５８９ｍｇ／ｍｌ,８．４１６ｍｇ／ｍｌ和６．６０６ｍｇ／ｍｌ;在体内可抑制连续给药１０ｄ大鼠血小板对ＡＤＰ和花生四烯酸诱导的血小板聚集,但对凝血酶诱导的血小板聚集无明显抑制作用。上述结果提示丹心Ⅲ号和丹心Ⅴ号对血小板聚集功     

广西眼镜蛇毒L-氨基酸氧化酶体内外抗血小板聚集实验研究

目的 研究广西眼镜蛇中提取的L-氨基酸氧化酶(L-amino acid oxidase)在人体外及家兔体内的抗血小板聚集作用.方法 用比浊法测定广西眼镜蛇毒L-氨基酸氧化酶对二磷酸腺苷(ADP)、胶原、凝血酶、花生四烯酸(AA)在人体外及家兔体内引起的血小板聚集率的影响.结果 实验中,能明显抑制二磷酸腺苷(ADP)、胶原、凝血酶、花生四烯酸(AA)引起的血小板聚集,并呈明显的正相关.结论 广西眼镜蛇毒L-氨基酸氧化酶在体内外均有较强的抗血小板聚集活性.     

丹心Ⅲ号和丹心V号对血小板聚集功能的影响

本文观察了丹心Ⅲ号和丹心Ｖ号对血小板聚集功能的影响,实验结果：丹心Ⅲ号和丹心Ｖ号在体外均可显著抑制ＡＤＰ和花生四烯酸诱导的人血小板聚集,其ＩＣ５０分别为１．６０５ｍｇ／ｍｌ,２．５８９ｍｇ／ｍｌ,８．４ｌ６ｍｇ／ｍｌ和６．６０６ｎｇ／ｍｌ;在体内可抑制连续给药（３５０一７００ｍｇ／ｌｋｇ．ｄ）１０ｄ大鼠血小板对ＡＤＰ和花生烯酸诱导的血小板聚集,但对凝血酶诱导的血小板聚集无明显抑制作用。上述结果提示丹心Ⅲ号和丹心Ⅴ号对血小板聚集功能具有明显的抑制作用。     

长角血蜱唾液腺中胶原特异性血小板聚集抑制因子的纯化及机制的研究

从长角血蜱唾液腺匀浆纯化出一种新的胶原特异性血小板聚集抑制因子 ,命名为“longicornin” ,它能特异性地抑制胶原诱导的血小板聚集反应 ,而对其他激动剂如ADP、花生四烯酸、凝血酶、瑞斯托霉素、A2 31 87、U46 6 1 9、乙酸豆寇佛波醇所诱导的纯化的血小板聚集均无抑制作用 .longicornin还能抑制血小板激活过程 ,包括血小板颗粒的释放和细胞间质游离Ca ²⁺浓度的升高 ,对胶原与血小板的粘附无抑制作用 .longicornin可能与胶原在血小板上有同一受体 ,并且与血小板受体的结合是可逆的 .     

华北绣线菊二萜生物碱抗血小板聚集活性研究

采用Born氏比浊法观察华北绣线菊小叶变种中分离得到的总碱和 9个hetisine型C2 0 二萜生物碱及其衍生物体外对血小板活化因子 (PAF)、花生四烯酸 (AA)和二磷酸腺苷 (ADP)三种诱导剂引起的血小板聚集活性的影响 ,并初步探讨了构效关系。结果表明 ,华北绣线菊小叶变种中总碱对PAF和ADP诱导的血小板聚集均有明显的抑制作用 ;9个hetisine型C2 0 二萜生物碱中 ,有 8个显著抑制PAF诱导的血小板聚集 ,其活性与分子结构明显相关 ;此外 ,hetisine型生物碱及其衍生物对ADP诱导的血小板聚集亦有一定的抑制作用 ,但总碱及生物碱对AA诱导的聚集影响不明显。提示hetisine型C2 0 二萜生物碱具有抗血小板聚集活性。     

天麻成分对羟基苯甲醛抗血小板聚集作用及急性毒性研究

为探讨天麻成分对羟基苯甲醛的抗血小板聚集作用,本实验以二磷酸腺苷(ADP)、花生四烯酸(AA)、血小板活化因子(PAF)为诱导剂,探讨了对羟基苯甲醛的体外抗血小板聚集活性;采用ADP静脉注射致小鼠肺栓塞方法以及下腔静脉结扎致大鼠静脉血栓方法,考察了对羟基苯甲醛的体内抗血小板聚集活性;并对经口给药的对羟基苯甲醛的急性毒性进行了检测。结果表明,天麻成分对羟基苯甲醛对ADP诱导的家兔体外血小板聚集有明显的对抗作用,其半数抑制率(50%inhibitory concentration,IC50)为2mmol/L,对PAF诱导的家兔体外血小板聚集无明显影响;天麻成分对羟基苯甲醛能明显降低小鼠肺栓塞死亡率,并显著对抗大鼠下腔静脉血栓的形成。说明天麻成分对羟基苯甲醛在体外、体内均具有显著的抗血小板聚集活性。急性毒性研究结果表明天麻成分对羟基苯甲醛经口给药的小鼠半数致死量(lethal dose 50,LD50)为1.23 g/kg。     

冠心病患者服用阿斯匹林、氯吡格雷前后血小板聚集功能比较

目的:通过比较冠心病患者单用或联用阿斯匹林、氯吡格雷前后血小板聚集功能,以指导临床用药.方法:将97例冠心病患者分成阿斯匹林组、氯吡格雷组和阿斯匹林与氯吡格雷两者联合用药组,比较各组用药前后四种不同诱导荆作用下血小板最大聚集率.结果:阿斯匹林组由花生四烯酸诱导血小板最大聚集率(29.9±11.0)与正常对照组(78.0±13.1)及用药前(96.8±8.1)比差异有非常显著意义;与之类似,氯吡格雷组由二磷酸腺苷诱导的血小板最大聚集率差异有非常显著意义;而联合用药组四种诱聚剂诱导的血小板最大聚集率差异均有显著意义.结论:阿斯匹林和氯吡格雷单用时对血小板聚集抑制作用仅限于ACA、ADP,而联合用药对四种诱聚剂均有抑制作用,因此联合用药对预防血栓形成更为有效.     

天麻醒脑胶囊对家兔血小板聚集和花生四烯酸诱导大鼠脑血栓形成的影响

采用比浊方法测定天麻醒脑胶囊在体内和体外对腺苷二磷酸（ADP）、花生四烯酸（arachidonic acid,AA）和血小板活化因子（platelet activating factor,PAF）诱导家兔血小板活化聚集的影响。采用从经大鼠颈内动脉注射诱发同侧大脑半球脑血栓形成方法评价天麻醒脑胶囊的抗脑血栓形成作用。天麻醒脑胶囊在体外呈浓度依赖性明显抑制从和ADP引起的血小板聚集,其半数抑制浓度（50％of inhibitory concentration,IC50）分别为1．83和3．25g/L。0．5和1g/kg的天麻醒脑胶囊于灌胃后明显抑制从诱导的家兔血小板聚集,本品1g/kg时显著阻抑ADP引起的血小板聚集。天麻醒脑胶囊在体内外对PAF诱导的血小板聚集均无明显影响。1、2g/kg天麻醒脑胶囊组的右侧与左侧脑重差值均显著减小,显著降低右脑伊文思蓝吸光度与右脑重的比值。结果提示,天麻醒脑胶囊具有较强的抗血小板和减轻脑血栓形成作用,有利于血小板聚集性增高的血栓栓塞性疾病的防治。     

烙铁头蛇毒素纤维蛋白原溶酶研究:Ⅱ.对纤维蛋白原及凝血酶的作用

烙铁头（T.mucrosquamatus）蛇毒纤维蛋白原溶酶TMVFg能水解三肽底物Bz-Phe-Val-Arg-PNA，但对凝血酶的良好底物Cbz-Gly-Pro-Arg-PNA却活性甚低。TMVFg显著延长血浆凝血酶时间、血浆复钙时间及纤维蛋白原溶液凝血酶时间。同时，TMVFg体外也能延长全血凝固时间，表明具有抗凝作用。纤维蛋白原-纤维蛋白转换实验表明：TMVFg水解纤维蛋白原产生的纤维蛋白原断片（FDP）除具有抗凝血酶，抑制纤维蛋白聚合活性外，还能促进纤维蛋白的聚合。进一步用FPLC分离TMVFg水解人纤维蛋白原混合液，得两个FDP断片功能峰，FDP组分Ⅰ和FDP组分Ⅱ。其中FDP组分Ⅰ能抑制纤维蛋白凝块形成；FDP组分Ⅱ能促进纤维蛋白凝块形成，抑制TMVA（烙铁头蛇毒血小板活化素，它可不通过ADP、花生四烯酸途径而诱导血小板聚集），但对ADP诱导的家兔血小板聚集无影响。TMVFg对凝血酶水解三肽底物Cbz-Gly-Pro-Arg-PNA及凝固纤维蛋白原的活性也有一定抑制作用。实验证明，TMVFg抗凝的主要作用机理是其水解纤维蛋白原产生的断片对纤维蛋白原凝固的抑制作用、FDP断片抗凝血酶作用及TMVFg本身对凝血酶活性的抑制所引起的，但在二者之间，前者是主要的。从研究结果发现：TMVFg水解纤维蛋白原所产生的断片有一类能加速凝血酶凝固纤维蛋白原的过程，这就发现了FDP断片的新功能。它证明了FDP断片作为血液凝固、纤溶正反馈调节因子的功能。这一类FDP断片还能抑制TMVA诱导的血小板聚集，因此，烙铁头蛇毒纤维蛋白原溶酶TMVFg将成为研究血液凝固调节系统及血小板聚集第三条途径的强有力试剂。     

烙铁头蛇毒纤维蛋白原溶酶研究——Ⅱ.对纤维蛋白原及凝血酶的作用

烙铁头(T.mucrosquamatus)蛇毒纤维蛋白原溶酶TMVFg能水解三肽底物Bz-Phe-Val-Arg-PNA,但对凝血酶的良好底物Cbz-Gly-Pro-Arg-PNA却活性甚低。TMVFS显著延长血浆凝血酶时间。血浆复钙时间及纤维蛋白原溶液凝血酶时间。同时,TMVFg体外也能延长全血凝固时间,表明具有抗凝作用。纤维蛋白原-纤维蛋白转换实验表明:TMVFg水解纤维蛋白原产生的纤维蛋白原断片(FDP)除具有抗凝血酶,抑制纤维蛋白聚合活性外,还能促进纤维蛋白的聚合。 进一步用FPLC分离TMVFg水解人纤维蛋白原混合液,得两个FDP断片功能峰,FDP组分Ⅰ和FDP组分Ⅱ。其中FDP组分Ⅰ能抑制纤维蛋白凝块形成;FDP组分Ⅱ能促进纤维蛋白凝块形成,抑制TMVA(烙铁头蛇毒血小板活化素,它可不通过ADP、花生四烯酸途径而诱导血小板聚集),但对ADP诱导的家兔血小板聚集无影响。TMVFg对凝血酶水解三肽底物Cbz-Gly-Pro-Arg-PNA及凝固纤维蛋白原的活性也有一定抑制作用。 实验证明,TMVFg抗凝的主要作用机理是其水解纤维蛋白原产生的断片对纤维蛋白原凝固的抑制作用、FDP断片抗凝血酶作用及TMVFg本身对凝血酶活性的抑制所引起的,但在二者之间,前者是主要的。 从研究结果发现:TMVFg水解纤维蛋白原所产生的断片有一类能加速凝血酶凝固纤维蛋白原的过程,这就发现了FDP断片的     

Effect of ultrafiltrates in plasma from patients with chronic uremia on platelet aggregation]

An effect of 20 ultrafiltrates from patients with chronic renal failure on ADP-, epinephrine-, and arachidonic acid-induced platelet aggregation. Ultrafiltrates were collected at the beginning and the end of dialysis. It was found that ultrafiltrates collected at the beginning of dialysis decrease ADP-induced platelet aggregation whereas ultrafiltrates collected at the and of dialysis exert reverse effect. No effect on epinephrine- and arachidonic acid-induced platelet aggregation was seen. Removal of substances inhibiting platelet aggregation produced by ADP hemodialysis may reveal increased platelet aggregation in patients with uremia.     

Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors

The inhibitory effect of Y-24180, 4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-t hieno [3,2-f][1,2,4]triazolo [4,3-a][1,4]diazepine, on platelet activating factor (PAF)-induced platelet aggregation and the specific binding of 3H-PAF to platelets was compared with other thienodiazepine derivatives, WEB 2086 and etizolam. Y-24180 inhibited PAF-induced rabbit platelet aggregation in vitro (IC50 3.84 nM), but had little effect on adenosine diphosphate- or arachidonic acid-induced aggregation. WEB 2086 and etizolam also showed an inhibitory effect of PAF-induced aggregation (IC50 values are 456 and 6730 nM, respectively). In PAF-induced human platelet aggregation, Y-24180 (IC50 0.84 nM) was more potent than WEB 2086 (IC50 4.21 nM) and etizolam (IC50 998 nM). Y-24180, WEB 2086 and etizolam displaced 3H-PAF binding from the washed-platelets of rabbits with an IC50 value of 3.50, 9.35 and 29.5 nM, respectively. In rabbits, pretreatment with Y-24180 and WEB 2086 antagonized PAF-induced platelet aggregation dose-dependently. The significant inhibitory effect of Y-24180 (1 mg/kg, p.o.) lasted 72 hr after a single dose oral administration. WEB 2086 (10 mg/kg, p.o.) also antagonized the ex vivo response induced by PAF 1 hr after administration, but no significant effect was observed 3 hr after administration. Y-24180 displaced 3H-diazepam binding from the synaptosomal membranes of rat cerebral cortex with a Ki value of 3.68 microM. The affinity of Y-24180 for benzodiazepine(BZP) receptors was lower than those of WEB 2086 and etizolam and was about 1000 times lower than that for PAF receptors in platelets.     

Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives

This paper describes the design, synthesis and pharmacological evaluation of new N-acylhydrazone (NAH) compounds, belonging to the N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone class (2a-p). Classical heteroaromatic ring bioisosterism strategies were applied to the previously reported N-phenylpyrazolyl-4-acylhydrazone derivative 1, elected as lead-compound due to its important anti-aggregating profile on arachidonic acid induced platelet aggregation (IC(50)=24+/-0.5 micro M), from which emerge this new series 2. These new compounds 2a-p were readily synthesized, characterized and tested on platelet aggregation assays induced by collagen (5 micro g/mL), ADP (5 micro M) and arachidonic acid (100 micro M) in rabbit citrated platelet-rich plasma. Compounds 2b, 2d, and 2h were found to be the most potent, exhibiting a significant antiplatelet activity on arachidonic acid- and collagen-induced platelet aggregation. In addition, these new antiplatelet agents are free of gastric ulcerogenic effect and presented discrete anti-inflammatory and analgesic properties. The N-para-chlorophenyltriazolyl-4-acylhydrazone compound 2h produced the highest inhibitory effect on collagen (IC(50)=21.6+/-0.4 micro M) and arachidonic acid-induced platelet aggregation (IC(50)=2.2+/-0.06 micro M), suggesting that the nature of the substituent on the phenyl ring of the N-heteroaromatic system of NAH moiety may be an important structural requirement for the improvement of antiplatelet activity, in comparison with lead-series 1.     

Antiplatelet property of Curcuma longa L. rhizome-derived ar-turmerone

The antiplatelet activities of Curcuma longa L. rhizome-derived materials were measured using a platelet aggregometer and compared with those of aspirin as antiplatelet agent. The active constituent from the rhizome of Curcuma longa L. was isolated and characterized as ar-turmerone by various spectral analyses. At 50% inhibitory concentration (IC50) value, ar-turmerone was effective in inhibiting platelet aggregation induced by collagen (IC50, 14.4 microM) and arachidonic acid (IC50, 43.6 microM). However, ar-turmerone had no effect on platelet activating factor or thrombin induced platelet aggregation. In comparison, ar-turmerone was significantly more potent platelet inhibitor than aspirin against platelet aggregation induced by collagen. These results suggested that ar-turmerone could be useful as a lead compound for inhibiting platelet aggregation induced by collagen and arachidonic acid.     

Prostacyclin: its biosynthesis, actions and clinical potential

Prostacyclin (PGI2) is the product of arachidonic acid metabolism generated by the vessel wall of all mammalian species studied, including man. Prostacyclin is a potent vasodilator and the most potent inhibitor of platelet aggregation so far described. Prostacyclin inhibits aggregation through stimulation of platelet adenyl cyclase leading to an increase in platelet cyclic AMP. In the vessel wall, the enzyme that synthesizes prostacyclin is concentrated in the endothelial layer. Prostacyclin can also be a circulating hormone released from the pulmonary circulation. Based on these observations we proposed that platelet aggregability in vivo is controlled via a prostacyclin mechanism. The discovery of prostacyclin has given a new insight into arachidonic acid metabolism and has led to a new hypothesis about mechanisms of haemostasis. Reductions in prostacyclin production in several diseases, including atherosclerosis and diabetes, have been described and implicated in the pathophysiology of these diseases. Additionally, since prostacyclin powerfully inhibits platelet aggregation and promotes their disaggregation, this agent could have an important use in the therapy of conditions in which increased platelet aggregation takes place and in which, perhaps, a prostacyclin deficiency exists. Prostacyclin has been used beneficially in humans during extracorporeal circulation procedures such as cardiopulmonary bypass, charcoal haemoperfusion and haemodialysis. Its possible use in other conditions such as peripheral vascular disease or transplant surgery is at present being investigated.     

Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis

Effects and the mechanism of the antiplatelet actions of beclobrinic acid, free acid form of a new hypolipidemic agent beclobrate [(+)-2-[d-(P-chlorophenyl)p-tolyl)oxy)-2-methyl-butyrate), were examined using human platelets. Platelet-rich plasma (PRP) which has been prelabeled with (14C)-serotonin was incubated with beclobrinic acid (BBA) for one minute before the addition of various agonists. BBA (0.1-1.5 mM) inhibited platelet aggregation and serotonin secretion induced by ADP, epinephrine, arachidonic acid and collagen in a concentration dependent manner. BBA also inhibited arachidonic acid-induced production of malondialdehyde (MDA), a byproduct of prostaglandins, in a concentration dependent manner. However, up to 1.0 mM BBA did not inhibit platelet aggregation induced by U46619, a stable analog of prostaglandin H2. In other experiments BBA also blocked thrombin-induced release of (3H)-arachidonic acid from platelet phospholipids. These findings suggest that: (a) BBA inhibits platelet aggregation and serotonin secretion by inhibiting prostaglandin synthesis at two steps. First by interfering in the release of arachidonic acid from platelet phospholipids and second by inhibiting its conversion into prostaglandins; and (b) BBA does not inhibit the action of prostaglandins on human platelets.     

Prostanoids and hemostasis in chickens: Anti-aggregating activity of the prostaglandins E1 and E2, but not of prostacyclin and prostaglandin D2

Aggregation of chicken thrombocytes was studied in whole blood using an electronic aggregometer. Serotonin (5-hydroxytryptamine, 5HT), arachidonic acid (AA) and collagen, but not adenosinediphosphate (ADP) induced aggregation. Prostaglandin (PG) endoperoxides were essential for arachidonic acid-induced aggregation, but were not involved in 5HT-induced aggregation, as indicated by inhibitory studies with indomethacin. Similar experiments indicated that biosynthesis of endogenous PG endoperoxides contributed to the aggregation induced by low concentrations of collagen, but was of little importance when high collagen doses were employed. PGE₁ and PGE₂ could abolish all types of aggregation studied, whereas prostacyclin (PGI₂) and PGD₂ were without any anti-aggregatory activity at 1 μg/ml. Between 1 and 100 ng/ml PGE₁ and PGE₂ inhibited arachidonic acid- and 5HT-induced aggregation dose-dependently.The lack of any hemostatic function of PGI₂ in chickens was also indicated by the absence of biosynthesis of endogenous PGI₂ in chicken aorta. PGI₂ was assessed as anti-aggregating activity, released by aortic fragments stirred in rabbit platelet rich plasma. Still, the presence of chicken aortic tissue i chicken whole blood inhibited 5HT-, but not arachidonic acid-induced aggregation. This inhibition was not affected by pretreatment of the aortic fragments with indomethacin or pargyline.     

Comparison of the effects of inhibitors of cytochrome P-450-mediated reactions on human platelet aggregation and arachidonic acid metabolism

Metyrapone and SKF-525A, together with amphenone B, a structural analogue of metyrapone, which are all inhibitors of cytochrome P-450-mediated reactions, were shown to inhibit the arachidonic acid-induced aggregation of human platelets. Amphenone B, like metyrapone, exhibited a type II (ligand) binding spectrum with rat liver microsomal cytochrome P-450, in contrast to SKF 525A which is a type I (substrate) binding agent. Independently of their type of binding spectra and of their maximum spectral change, however, the affinity of the three compounds for rat liver cytochrome P-450 showed a close proportional correlation with their platelet aggregation inhibitory potency. All three compounds inhibited the formation of [1-14C]thromboxane B2 from [1-14C]arachidonic acid by human platelets aggregated with collagen. The effect of metyrapone on the remaining labelled products suggested that it is a selective thromboxane synthesis inhibitor, while amphenone B exhibited activity reminiscent of cyclo-oxygenase inhibitors. SKF 525A produced complex effects possibly attributable to cyclo-oxygenase inhibition and enhanced lipid peroxidation, since it also enhanced platelet malonaldehyde formation, which the other two compounds inhibited. These data provide further support for a role of cytochrome P-450 in thromboxane synthesis and platelet aggregation.     

Inhibition of platelet aggregation by unsaturated fatty acids through interference with a thromboxane-mediated process

cis- and trans-unsaturated fatty acids with 18 carbon atoms (oleic, linoleic, elaidic and linolelaidic acid) inhibited aggregation of washed rabbit platelets stimulated with collagen, arachidonic acid and U46619 when in the same concentration ranges. Thrombin-induced aggregation was not affected by any of them. Saturated fatty acid (stearic acid) had no effect on this response. The inhibition is independent of the induced change in membrane fluidity, since trans-isomers could not induce the change in fluorescence polarization of 1,6-diphenyl-1,3,5-hexatriene. Unsaturated fatty acids, except linoleic acid, did not interfere with the formation of thromboxane B2 from exogenously added arachidonic acid. All the unsaturated fatty acids only slightly inhibited the arachidonic acid liberation by phospholipase A2 in platelet lysate. This indicates that the unsaturated fatty acids may block a process after formation of thromboxane A2 in response to collagen and arachidonic acid. The increase in phosphatidic acid formation stimulated with U46619 was inhibited dose dependently by each of the unsaturated fatty acids but that stimulated with thrombin was not affected by any of them. Phospholipase C activity measured by diacylglycerol formation in unstimulated platelet lysate was not inhibited by the fatty acids. The elevation of cytosolic free Ca2+ induced by arachidonic acid or U46619 and Ca2+ influx by collagen were inhibited almost completely at the same concentration as that which inhibited their aggregation. These data suggest that the unsaturated fatty acids were intercalated into the membrane and inhibited collagen- and arachidonic acid-induced platelet aggregation by causing a significant suppression of the thromboxane A2-mediated increase in cytosolic free Ca2+, probably due to interference with the receptor-operated Ca2+ channel.     

Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets

S-Nitroso-cysteine (SNC), a putative endothelium-derived relaxing factor, potently inhibited collagen- and arachidonic acid-induced platelet aggregation (IC₅₀=100 nM) and thromboxane A₂ (TxA₂) synthesis of human blood platelets. ODQ, a selective inhibitor of the soluble guanylyl cyclase, inhibited SNC-induced formation of cGMP but did not reverse inhibition by SNC of collagen- and arachidonic acid-induced platelet aggregation. Combination of ODQ with SQ-29548, a specific platelet TxA₂ receptor antagonist, did not modify the antiaggregatory action of SNC. Our study shows that SNC inhibits platelet aggregation by cGMP-independent mechanisms that may involve inhibition of TxA₂ synthesis in human platelets.